Abingdon Health
York Biotech Campus,
YO41 1LZ
York
United Kingdom of Great Britain and Northern Ireland
United Kingdom of Great Britain and Northern Ireland
Media files
Contact
Our range of products
Product categories
- 03 Diagnostic tests
- 03.01 Clinical chemistry
- 03.01.04 Rapid tests in clinical chemistry
Rapid tests in clinical chemistry
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.02 Diagnostic rapid tests
Diagnostic rapid tests
- 03 Diagnostic tests
- 03.04 Microbiology testing
- 03.04.03 Rapid tests in microbiology
Rapid tests in microbiology
Our products
Product category: Rapid tests in clinical chemistry, Diagnostic rapid tests, Rapid tests in microbiology
Rapid Test Development
Focused on meeting our customers’ needs: Our lateral flow rapid test development service produces diagnostics systems that enhance end-user experience, deliver accurate results and improve diagnosis turnaround times.
We ensure our meticulous approach and assistance in commercial and regulatory planning, if required, develops rapid testing solutions on time and within budget. Our rapid test manufacturing team are involved early in the development process to ensure successful scale-up to routine manufacture.
Being a part of your assay’s journey from concept through to a market leading rapid test is what drives us to succeed.
This year Abingdon Health developed and manufactured AbC-19, a rapid test for detecting SARS-CoV-2 IgG neutralising antibodies.
Connect with Leigh or Jonathan via Medica's networking platform to arrange a consultation.
We ensure our meticulous approach and assistance in commercial and regulatory planning, if required, develops rapid testing solutions on time and within budget. Our rapid test manufacturing team are involved early in the development process to ensure successful scale-up to routine manufacture.
Being a part of your assay’s journey from concept through to a market leading rapid test is what drives us to succeed.
This year Abingdon Health developed and manufactured AbC-19, a rapid test for detecting SARS-CoV-2 IgG neutralising antibodies.
Connect with Leigh or Jonathan via Medica's networking platform to arrange a consultation.
Product category: Rapid tests in clinical chemistry, Diagnostic rapid tests, Rapid tests in microbiology
Rapid Test Manufacturing
Supporting your products’ growth with consistency and efficiency: Abingdon Health provides specialist assay development and smartphone reader solutions alongside Europe’s largest lateral flow test manufacturing capacity. By combining a multi-disciplinary approach with precision automation Abingdon Health assures product consistency and security of supply for the most complex of assays and markets.
Our manufacturing service is available to internal assay development customers or clients looking to meet demand or reach new territories with a new or 2nd manufacturer.
This year Abingdon Health developed and manufactured AbC-19, a rapid test for detecting SARS-CoV-2 IgG neutralising antibodies.
We are dedicated on supporting your plans and helping you grow your business.
Connect with Leigh or Jonathan via Medica's networking platform to arrange a consultation.
Our manufacturing service is available to internal assay development customers or clients looking to meet demand or reach new territories with a new or 2nd manufacturer.
This year Abingdon Health developed and manufactured AbC-19, a rapid test for detecting SARS-CoV-2 IgG neutralising antibodies.
We are dedicated on supporting your plans and helping you grow your business.
Connect with Leigh or Jonathan via Medica's networking platform to arrange a consultation.
Product category: Rapid tests in clinical chemistry, Diagnostic rapid tests, Rapid tests in microbiology
Smartphone reader solutions
Improving health outcomes with rapid data solutions: AppDx® is cutting-edge mHealth software that turns a Smartphone into a lateral flow reader. By utilising cameras and connectivity within Smartphones, AppDx® enables data to be captured from rapid tests and shared to secure data silos and connected stakeholders.
AppDx® can be configured with existing lateral flow assay formats or incorporated into new lateral flow assay development projects.
Connect with Leigh or Jonathan via Medica's networking platform to arrange a demonstration of AppDx® .
AppDx® can be configured with existing lateral flow assay formats or incorporated into new lateral flow assay development projects.
Connect with Leigh or Jonathan via Medica's networking platform to arrange a demonstration of AppDx® .
Company news
Date
Topic
Download
Oct 6, 2020
UK Government enters into a contract with Abingdon Health for supply of COVID-19 rapid antibody tests
The UK Government has entered into a contract with Abingdon Health, on behalf of the UK-Rapid Test Consortium (“UK-RTC”), for the supply of the AbC-19 Rapid Test. As part of the contract the UK Government has placed its first order for one million COVID-19 rapid antibody tests.
This follows an independent evaluation commissioned by the UK government of the AbC-19 Rapid Test, which will be published in full in due course by PHE, after peer review.
AbC-19 uses a small drop of blood from a finger-prick, and shows results in 20 minutes, without the need to go to a specialised laboratory.
The test can be administered by healthcare professionals, such as doctors, nurses, pharmacists and healthcare workers, at the point-of-care. It has already received the “CE mark”, which indicates health and safety conformity for goods sold in the UK and EU.
The antibody test has been developed for the Department of Health and Social Care in response to the Government’s need to procure a high-quality antibody test.
To develop and mass produce the volumes needed for the UK population, Abingdon Health set up and led the UK-RTC in April this year. The consortium brings together the UK’s largest rapid test medical manufacturers, working together to provide capacity for delivery of more than a million tests per week
The test detects IgG antibodies to “full trimeric spike proteins” of the SARS-CoV-2 virus. This means the test detects those antibodies which interfere with the virus’s ability to enter the human cells.
Click on the link to read the full story.
This follows an independent evaluation commissioned by the UK government of the AbC-19 Rapid Test, which will be published in full in due course by PHE, after peer review.
AbC-19 uses a small drop of blood from a finger-prick, and shows results in 20 minutes, without the need to go to a specialised laboratory.
The test can be administered by healthcare professionals, such as doctors, nurses, pharmacists and healthcare workers, at the point-of-care. It has already received the “CE mark”, which indicates health and safety conformity for goods sold in the UK and EU.
The antibody test has been developed for the Department of Health and Social Care in response to the Government’s need to procure a high-quality antibody test.
To develop and mass produce the volumes needed for the UK population, Abingdon Health set up and led the UK-RTC in April this year. The consortium brings together the UK’s largest rapid test medical manufacturers, working together to provide capacity for delivery of more than a million tests per week
The test detects IgG antibodies to “full trimeric spike proteins” of the SARS-CoV-2 virus. This means the test detects those antibodies which interfere with the virus’s ability to enter the human cells.
Click on the link to read the full story.
Sep 17, 2020
Abingdon Health announces £1M funding for the development of a quantitative rapid test Smartphone Reader
Innovate UK has released £1M to fund a further next generation development of Abingdon Health’s lateral-flow rapid test readout technology; AppDx®. The project will see the enhancement of AppDx® at an accelerated pace to achieve a fully quantitative smartphone-based solution for the lateral flow assay (LFA) market.
AppDx® is cutting-edge software that transforms a Smartphone camera into a self-sufficient, standalone lateral-flow reader. By utilising connectivity within Smartphones, AppDx® then enables data captured from rapid tests to be securely shared via a data cloud to connected stakeholders.
AppDx® algorithms work under a “bring-your-own-device” model and the software considers test specific and end-user variables as well as vital configuration criteria for different phone models.
Click on the link to read the full story.
AppDx® is cutting-edge software that transforms a Smartphone camera into a self-sufficient, standalone lateral-flow reader. By utilising connectivity within Smartphones, AppDx® then enables data captured from rapid tests to be securely shared via a data cloud to connected stakeholders.
AppDx® algorithms work under a “bring-your-own-device” model and the software considers test specific and end-user variables as well as vital configuration criteria for different phone models.
Click on the link to read the full story.
About us
Company details
Improving life with rapid testing. Abingdon Health provides lateral flow assay development alongside Europe’s largest rapid test manufacturing capcity to a multi-industry, global client base.
A multi-disciplinary team forms the foundations of our services and a partnership-led approach alongside a focus on operational excellence produces reliable products irrespective of their complexity. Established supply chain and manufacturing processes are tailored to assay specifications and market demand for continuity of supply.
Abingdon Health is the lead manufacturer of AbC-19, a rapid test for the detection of IgG neutralising antibodies to SARS-CoV-2 (COVID-19). The test was developed by Abingdon Health on behalf of the UK Rapid Test Consortium (UK-RTC).
Abingdon Health is headquartered in York, UK, with additional sites across the UK in Doncaster and Birmingham.
A multi-disciplinary team forms the foundations of our services and a partnership-led approach alongside a focus on operational excellence produces reliable products irrespective of their complexity. Established supply chain and manufacturing processes are tailored to assay specifications and market demand for continuity of supply.
Abingdon Health is the lead manufacturer of AbC-19, a rapid test for the detection of IgG neutralising antibodies to SARS-CoV-2 (COVID-19). The test was developed by Abingdon Health on behalf of the UK Rapid Test Consortium (UK-RTC).
Abingdon Health is headquartered in York, UK, with additional sites across the UK in Doncaster and Birmingham.
Company data
Number of employees100-499
Occupational sector- Electromedical equipment / Medical Technology
- Diagnostics